FDA OKs trial of Terumo protocol for polymorphonuclear cells

01/8/2013 | InnovatioNews

The FDA has approved a trial to assess a collection protocol for polymorphonuclear cells using the Spectra Optia platform, according to Terumo BCT. Polymorphonuclear cells from donors could help patients whose immune systems are compromised due to illness or chemotherapy.

View Full Article in:

InnovatioNews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT